Neuroectodermal interleukin 12 signaling attenuates spinal cord inflammation and demyelination

Area of Science:

• Neuroimmunology
• Inflammation research
• Autoimmune diseases

Background:

• Interleukin 12 (IL-12) drives type 1 immunity and reduces inflammation in spinal cord autoimmune conditions.
• Investigating the therapeutic potential of IL-12 in experimental autoimmune encephalomyelitis (EAE) is crucial.

Purpose of the Study:

• To investigate the therapeutic effect of IL-12 in the EAE model.
• To determine the cellular sources and mechanisms of IL-12's neuroprotective actions.

Main Methods:

• Mapping Interleukin 12 (IL-12) expression in neurons, oligodendrocytes, natural killer cells, and T lymphocytes in EAE mice.
• Analyzing the impact of IL-12 ablation in specific cell types on EAE susceptibility.
• Utilizing single-nucleus RNA sequencing to uncover IL-12 receptor-mediated effects.

Main Results:

• IL-12 ablation in neurons, oligodendrocytes, natural killer cells, and T lymphocytes increased susceptibility to EAE.
• The neuroprotective role of IL-12 was found to be mediated by neuroectoderm-derived cells, specifically neurons.
• Single-nucleus RNA sequencing identified IL-12 receptor-induced pathways.

Conclusions:

• IL-12 exerts a neuroprotective effect in EAE, mediated primarily by neurons.
• IL-12 signaling prevents neurodegeneration and maintains spinal cord integrity during neuroinflammation.
• IL-12 sustains trophic factor release, contributing to its therapeutic benefits in autoimmune spinal cord conditions.